ME1 and breast cancer: Consistently, analysis of patient-derived breast cancer cell lines (CCLE dataset) showed that 25% (12/48) of cell lines have ME1 copy number amplification (Fig. 2g), 66.67% (8/12) of which belonged to BLBC subtype (Fig. 2h).